Division of Product Quality Research, Office of Pharmaceutical Science, Food and Drug Administration, Life Science Building 64, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.
J Pharm Biomed Anal. 2010 Apr 6;51(5):1108-12. doi: 10.1016/j.jpba.2009.11.017. Epub 2009 Nov 24.
Lanthanum carbonate is indicated to reduce serum phosphate in patients with end stage renal disease (ESRD). When given orally, lanthanum carbonate dissociates in the acid environment of the upper gastrointestinal tract to release lanthanum ions. The free lanthanum ions bind with dietary phosphate released from food during digestion to form highly insoluble lanthanum-phosphate complexes which prevent the absorption of phosphate, consequently reduce the serum phosphate. In order to evaluate the in vitro binding capacity of lanthanum carbonate, a simple and efficient ion chromatography (IC) method was developed and validated for determination of phosphate across the pH range encountered in the gastrointestinal tract. Chromatographic separation was achieved on a Dionex ICS-2000 IC system using a Dionex AS16, IonPac (4mmx250mm) analytical column and Dionex AG16, IonPac (4mmx50mm) guard column. Column temperature was maintained at 30 degrees C. Injection volume was 10microL. The compounds were eluted isocratically at a flow rate of 1mL/min and detected by suppressed conductivity. The analytical method was validated according to USP Category I requirements. The validation characteristics included accuracy, precision, quantification limit, linearity, and stability. The intra-day accuracy ranged from 89% to 103% for the solutions of pH 1.2-6.8. The intra-day precision (RSD) ranged from 0.6% to 3.7% for the solutions of pH 1.2-6.8. The analytical range was linear from 2 to 200ppm (mg/L). The R(2) ranged from 0.9998 to 1.0. This method was found to be simple, robust, sensitive, specific, and accurate. It has been successfully applied for determination of phosphate binding to lanthanum carbonate over the human gastrointestinal pH range at different time-points (from 0.5 to 24h).
碳酸镧被用于降低终末期肾病(ESRD)患者的血清磷酸盐水平。当口服时,碳酸镧在胃上部的酸性环境中解离,释放出镧离子。游离的镧离子与食物消化过程中从食物中释放的磷酸盐结合,形成高度不溶的镧-磷酸盐复合物,从而阻止磷酸盐的吸收,进而降低血清磷酸盐水平。为了评估碳酸镧的体外结合能力,开发并验证了一种简单高效的离子色谱(IC)方法,用于测定胃肠道中遇到的 pH 范围内的磷酸盐。在 Dionex ICS-2000 IC 系统上,使用 Dionex AS16、IonPac(4mmx250mm)分析柱和 Dionex AG16、IonPac(4mmx50mm)保护柱进行色谱分离。柱温保持在 30°C。进样量为 10μL。化合物在 1mL/min 的流速下进行等度洗脱,并通过抑制电导进行检测。该分析方法根据 USP 类别 I 的要求进行了验证。验证特性包括准确性、精密度、定量限、线性和稳定性。对于 pH 值为 1.2-6.8 的溶液,日内准确度范围为 89%-103%。对于 pH 值为 1.2-6.8 的溶液,日内精密度(RSD)范围为 0.6%-3.7%。分析范围线性从 2 到 200ppm(mg/L)。R²范围从 0.9998 到 1.0。该方法简单、稳健、灵敏、特异、准确。已成功应用于不同时间点(0.5-24 小时)人胃肠道 pH 范围内测定碳酸镧与磷酸盐的结合。